Headache

  • Marc E. Lenaerts
  • James R. CouchJr.

Abstract

Headache is one of the most common complaints of patients seeking medical attention. There are several important indications to warrant investigation of a headache: a patient’s first or worst headache; a recent change in the patient’s headache pattern; new neurologic findings; no response to treatment; and symptoms that do not correspond to a primary headache such as migraine, tension-type, or cluster [1].

Keywords

Cluster Headache Trigeminal Neuralgia Giant Cell Arteritis Migraine Patient Migraine With Aura 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Couch JR: Headache to worry about. Med Clin North Am 1993, 77: 141–167.PubMedGoogle Scholar
  2. 2.
    Rasmussen BK, Jensen R, Schroll M, Olesen J: Epidemiology of headache in a general population—a prevalence study. J Clin Epidemiol 1991, 44 (11): 1147–1157.PubMedCrossRefGoogle Scholar
  3. 3.
    Lipton RB, Stewart WF: Migraine in the United States: a review of epidemiology and health care use. Neurology 1993, 43: S6 - S10.PubMedGoogle Scholar
  4. 4.
    Schwartz BS, Stewart WF, Simon D, Lipton RB: Epidemiology of tension-type headache. JAMA 1998, 279 (5): 381–383.PubMedCrossRefGoogle Scholar
  5. 5.
    Headache Classification Committee of the International Headache Society: Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia 1988, 7: 1–96.Google Scholar
  6. 6.
    Launer LJ, Terwindt GM, Ferrari MD: The prevalence and characteristics of migraine in a population-based cohort: the GEM study. Neurology 1999, 53 (3): 537–542.PubMedCrossRefGoogle Scholar
  7. 7.
    Stewart WF, Linet MS, Celentano DD, et al.: Age-and sex-specific incidence rates of migraine with and without aura. Am J Epidemiol 1991, 134:1111–1120.Google Scholar
  8. 8.
    S. Stewart WF, Lipton RB, Liberman J: Variation in migraine prevalence by race. Neurology 1996, 47 (1): 52–59.PubMedCrossRefGoogle Scholar
  9. 9.
    Lipton RB, Stewart WF: Acute migraine therapy. Headache 1999, 39: S20 - S26.CrossRefGoogle Scholar
  10. 10.
    Hu XH, Markson LE, Lipton RB, et al.: Burden of migraine in the United States: disability and economic costs. Arch Intern Med 1999, 159(8):813–818.Google Scholar
  11. 11.
    Terwindt GM, Ferrari MD, Tijhuis M, et al.: The impact of migraine on quality of life in the general population: the GEM study. Neurology 2000, 55:624–629.Google Scholar
  12. 12.
    Couch JR: Complexities of presentation and pathogenesis of migraine headache. In Treating the Headache Patient. Edited by Cady RK, Fox AW. New York: Marcel Dekker; 1995.Google Scholar
  13. 13.
    Lenaerts M: Migraine and epilepsy: comorbidity and temporal relationship. Paper presented at: Ninth Congress of the International Society; June 1999; Barcelona, Spain.Google Scholar
  14. 14.
    Merikangas KR, Merikangas JR, Angst J: Headache syndromes and psychiatric disorders: association and familial transmission. J Psychiatr Res 1993, 27: 197–210.PubMedCrossRefGoogle Scholar
  15. 15.
    Olesen J, Tfelt-Hansen P, Welch KMA: The Headaches. New York: Raven Press; 1993: 256–266.Google Scholar
  16. 16.
    Lennox WG, Gibbs EL, Gibbs FA: Effect of ergotamine tartrate on the cerebral circulation of man. J Pharmacol Exp Ther 1935, 53: 113.Google Scholar
  17. 17.
    Ledo AAP: Spreading depression of activity in cerebral cortex. J Neurophysiol 1944, 7: 359–390.Google Scholar
  18. 18.
    Lashley KS: Patterns of cerebral integration indicated by scotomas of migraine. Arch Neurol Psychiat 1941, 46: 331.CrossRefGoogle Scholar
  19. 19.
    Lauritzen M, Olesen J: Regional cerebral blood flow during migraine attacks by Xenon-133 inhalation and emission tomography. Brain 1984, 107: 447–461.PubMedCrossRefGoogle Scholar
  20. 20.
    Olesen J, Friberg L, Olsen TS, et al.: Timing and topography of cerebral blood flow, aura, and headache during migraine attacks. Ann Neurol 1990, 28:791–798.Google Scholar
  21. 21.
    Cutrer FM, Sorensen AG, Weisskoff RM, et al.: Perfusion-weighted imaging defects during spontaneous migrainous aura. Ann Neurol 1998, 43:25–31.Google Scholar
  22. 22.
    Woods RP, Iacoboni M, Mazziotta JC: Brief report: bilateral spreading cerebral hypoperfusion during spontaneous migraine headache. N Engl J Med 1994, 331: 1689–1692.PubMedCrossRefGoogle Scholar
  23. 23.
    Weiner C, May A, Limmroth V, et al.: Brain stem activation in spontaneous human migraine attacks. Nat Med 1995, 1:658–660.Google Scholar
  24. 24.
    Raskin NH, Hosobuchi Y, Lamb S: Headache may arise from perturbation of brain. Headache 1987, 27: 416–420.PubMedCrossRefGoogle Scholar
  25. 25.
    Goadsby PJ, Edvinsson L, Ekman R: Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 1990, 28: 183–187.PubMedCrossRefGoogle Scholar
  26. 26.
    Moskowitz MA: Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13: 307–311.PubMedCrossRefGoogle Scholar
  27. 27.
    Goadsby PJ, Zagami AS, Lambert GA: Neural processing of craniovascular pain: a synthesis of the central-structures involved in migraine. Headache 1991, 31: 365–371.PubMedCrossRefGoogle Scholar
  28. 28.
    Schoenen REF: Contingent negative variation: methods and potential interest in headache. Cephalalgia 1993, 13 (1): 28–32.PubMedCrossRefGoogle Scholar
  29. 29.
    tlfra J, Cecchini AP, DePasqua V, et al.: Visual evoked potentials during long periods of pattern-reversal stimulation in migraine. Brain 1998, 121:233–241.Google Scholar
  30. 30.
    Wang W, Lenaerts M, Schoenen J: Reduced habituation of pattern-reversal visual evoked responses in migraine. Paper presented at: International Conference of the European Headache Federation; June 1994; Liege, Belgium.Google Scholar
  31. 31.
    Welch KMA, Cao Y, Aurora S, et al.: MRI of the occipital cortex, red nucleus, and substantia nigra during visual aura of migraine. Neurology 1998, 51:1465–1469.Google Scholar
  32. 32.
    Joutel A, Bousser MG, Biousse V, et al.: A gene for familial hemiplegic migraine maps to chromosome 19. Nat Genet 1993, 5:40–45.Google Scholar
  33. 33.
    Ophoff RA, Terwindt GM, Vergouwe MN, et al.: Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Ce11 1996, 87:543–552.Google Scholar
  34. 34.
    Barbiroli B Montagna P, Cortelli P, et al.: Abnormal brain and muscle metabolism shown by 31P magnetic resonance spectroscopy in patients affected by migraine with aura. Neurology 1992, 42:1209–1214.Google Scholar
  35. 35.
    Welch KM, Levine SR, D’Andrea G, et al.: Preliminary observation on brain energy metabolism in migraine studied by in vivo phosphorus 31 NMR spectroscopy. Neurology 1989, 39:538–541.Google Scholar
  36. 36.
    Ferrari MD, Odink J, Tapparelli C, et al.: Serotonin metabolism in migraine. Neurology 1989, 39:1239–1242.Google Scholar
  37. 37.
    Humphrey PPA: 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991, 238:S38–S44.Google Scholar
  38. 38.
    Ferrari MD: Systemic biochemistry. In The Headaches. Edited by Olesen J, Tfelt-Hansen P, Welch KMA. New York: Raven Press; 1993: 179–183.Google Scholar
  39. 39.
    Parsons AA, Whalley ET: Characterization of the 5-HT receptor which mediates contraction of the human isolated basilar artery. Cephalalgia 1989, 9 (S9): 47–51.PubMedGoogle Scholar
  40. 40.
    Fozard JR, Kalkman HO: 5-HT in nervous system disease and migraine. Curr Opin Neural Neurosurg 1992, 5 (4): 496–502.Google Scholar
  41. 41.
    Peroutka SJ: Antimigraine drug interactions with serotonin receptor subtypes in human brain. Ann Neural 1988, 23 (5): 500–504.CrossRefGoogle Scholar
  42. 42.
    Peroutka SJ: Dopamine and migraine. Neurology 1997, 49 (3): 650–656.PubMedCrossRefGoogle Scholar
  43. 43.
    Goadsby PJ: The pathophysiology of primary headache. In Headache in Clinical Practice. Edited by Silberstein SD, Lipton RB, Goadsby PJ. Oxford: ISIS Medical Media; 1998.Google Scholar
  44. 44.
    Storer RJ, Goadsby PJ: Trigeminovascular nociceptive transmission involves N-methyl-D-aspartate and non-N-methyl-D-aspartate glutamate receptors. Neuroscience 1999, 90 (4): 1371–1376.PubMedCrossRefGoogle Scholar
  45. 45.
    Schoenen J, Sianard-Gainko J, Lenaerts M: Blood magnesium levels in migraine. Cephalalgia 1991, 11: 97–99.PubMedCrossRefGoogle Scholar
  46. 46.
    Ramadan NM, Halvorson H, Vande-Linde A, et al. Low brain magnesium level in migraine. Headache 1989, 29 (7): 416–419.PubMedCrossRefGoogle Scholar
  47. 47.
    Somerville BM: The role of estradiol withdrawal in the etiology of menstrual migraine. Neurology 1972, 22: 355–365.PubMedCrossRefGoogle Scholar
  48. 48.
    Welch KMA, Darnley D, Simkins RT: The role of estrogens in migraine: a review and hypothesis. Cephalalgia 1984, 4: 227–236.PubMedCrossRefGoogle Scholar
  49. 49.
    Mathew NT, Kailasam J, Meadors L, et al.: Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report. Headache 2000, 40(9):720–723.Google Scholar
  50. 50.
    Goadsby PJ, Hargreaves RJ: Mechanisms of action of serotonin 5-HT1B/D agonists: insights into migraine pathophysiology using rizatriptan. Neurology 2000, 55: S8 - S14.PubMedGoogle Scholar
  51. 51.
    Goadsby PJ: The scientific basis of medication choice in symptomatic migraine treatment. Can J Neurol Sci 1999, 26: 20–26.Google Scholar
  52. 52.
    Humphrey PP, Feniuk W: Mode of action of the anti-migraine drug sumatriptan. Trends Pharmacol Sci 1991, 12: 444–446.PubMedCrossRefGoogle Scholar
  53. 53.
    Silberstein SD: Rizatriptan versus usual care in long-term treatment of migraine. Neurology 2000, 55: S25 - S28.PubMedCrossRefGoogle Scholar
  54. 54.
    Solomon GD, Cady RK, Klapper JA, et al.: Clinical efficacy and tolerability of 2.5 mg zolmitriptan for the acute treatment of migraine. Neurology 1997, 49:1219–1225.Google Scholar
  55. 55.
    Nappi G, Sicuteri F, Byrne M, et al.: Oral sumatriptan compared with placebo in the acute treatment of migraine. J Neurol 1994, 241:138–144.Google Scholar
  56. 56.
    Sargent J, Kirchner J, Davis R, Kirkhart B: Oral sumatriptan is effective and well tolerated for the acute treatment of migraine: results of a multicenter study. Neurology 1995, 45: S10 - S14.PubMedGoogle Scholar
  57. 57.
    Tfelt-Hansen P, Ryan RE Jr: Oral therapy for migraine: comparisons between rizatriptan and sumatriptan. A review of four randomized, double-blind clinical trials. Neurology 2000, 55: S19 - S24.PubMedGoogle Scholar
  58. 58.
    The International 311C90 Long-term Study Group: The long-term tolerability and efficacy of oral zolmitriptan (Zomig, 311C90) in the acute treatment of migraine. An international study. Headache 1998, 38: 173–183.Google Scholar
  59. 59.
    Cady RK, Lipton RB, Hall C, et al.: Treatment of mild headache in disabled migraine sufferers: results of the Spectrum Study. Headache 2000, 40(10):792–797.Google Scholar
  60. 60.
    Lipton RB, Stewart WF, Cady R, et al.: Sumatriptan for the range of headaches in migraine sufferers: results of the Spectrum Study. Headache 2000, 40(10):1–9.Google Scholar
  61. 61.
    Raskin NH: Repetitive intravenous dihydroergotamine as therapy for intractable migraine. Neurology 1986, 36 (7): 995–997.PubMedCrossRefGoogle Scholar
  62. 62.
    Goadsby PJ: How do the currently used prophylactic agents work in migraine? Cephalalgia 1997, 17: 85–92.PubMedCrossRefGoogle Scholar
  63. 63.
    Breslau N, Merikangas K, Bowden CL: Comorbidity of migraine and major affective disorders. Neurology 1994, 44: S17 - S22.PubMedGoogle Scholar
  64. 64.
    Breslau N, Davis GC, Schultz LR, Peterson EL: Migraine and major depression: a longitudinal study. Headache 1994, 34: 387–393.PubMedCrossRefGoogle Scholar
  65. 65.
    Schoenen J, Jacquy J, Lenaerts M: Effectiveness of high-dose riboflavin in migraine prophylaxis. A randomized controlled trial. Neurology 1998, 50: 466–470.PubMedCrossRefGoogle Scholar
  66. 66.
    Silberstein SD, Silberstein MM: New concepts in the pathogenesis of headache: migraine versus tension-type headache. Phys Assist 1991, 9: 67–81.Google Scholar
  67. 67.
    Jensen R, Olesen J: Initiating mechanisms of experimentally-induced tension-type headache. Cephalalgia 1996, 16: 175.PubMedCrossRefGoogle Scholar
  68. 68.
    Schoenen J, Sandor P: Headache. In Textbook of Pain, edn 4. Edited by Wall PD, Melzack R. New York: Churchill Livingstone; 1999.Google Scholar
  69. 69.
    Lance JW, Ekbom K: In Cluster Headaches: Mechanism and Management. Edited by Kudrow L. New York: Oxford University Press; 1980: 27–28.Google Scholar
  70. 70.
    Hardebo JE: On pain mechanisms in cluster headache. Headache 1991, 31: 91–106.PubMedCrossRefGoogle Scholar
  71. 71.
    May A, Bahra A, Büchel, et al.: PET and MRA findings in cluster headache and MRA in experimental pain. Neurology 2000, 55:1328–1335.Google Scholar
  72. 72.
    Lenaerts M, Couch JR: Trigeminal neuralgia. Emedicine [serial online]. 2001. Available at: http://www.emedicine.com/oph/NEUROLOGIC_DISORDERS.htm. Accessed January 25, 2001.Google Scholar
  73. 73.
    Blom S: Trigeminal neuralgia: a treatment with a new anticonvulsant drug. Lancet 1962, 1: 839–840.PubMedCrossRefGoogle Scholar
  74. 74.
    Fromm GH, Terrence CF, Chattha AS: Baclofen in the treatment of trigeminal neuralgia: double-blind study and long-term follow-up. Ann Neurol 1984, 15 (3): 240–244.PubMedCrossRefGoogle Scholar
  75. 75.
    McLaughlin MR, Jannetta PJ, Clyde BL, et al.: Microvascular decompression of cranial nerves: lessons learned after 4400 operations. J Neurosurg 1999, 90(1):1–8.Google Scholar
  76. 76.
    Evans RW, Armon C, Frohman EM, Goodin DS: Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2000, 55: 909–914.PubMedCrossRefGoogle Scholar
  77. 77.
    Lenaerts M, Pepin JL, Tombu S, Schoenen J: No significant effect of an “atraumatic” needle on the incidence of post-lumbar puncture headache or traumatic tap. Cephalalgia 1993, 13: 296–297.PubMedCrossRefGoogle Scholar
  78. 78.
    Williams E, Fawcett W, Jenkins G: Preventing headache after lumbar puncture. Optimism generally quoted for epidural blood patching is unwarranted. BMJ 1998, 317: 1588–1589.PubMedGoogle Scholar
  79. 79.
    Panagopoulos G, Gotsi A, Piaditis G, et al.: Treatment of benign intracranial hypertension with octreotide [abstract]. American Academy of Neurology. 1998.Google Scholar
  80. 80.
    Lou L: Uncommon areas of electrical stimulation for pain relief. Curr Rev Pain 2000, 4 (5): 407–412.PubMedCrossRefGoogle Scholar
  81. 81.
    Weiner RL: The future of peripheral nerve neurostimulation. Neurol Res 2000, 22: 299–303.PubMedGoogle Scholar
  82. 82.
    Sjaastad O, Saunte C, Hovdahl H, et al.: “Cervicogenic” headache: a hypothesis. Cephalalgia 1983, 3(4):249–256Google Scholar
  83. 83.
    Sjaastad O, Fredriksen TA, Pfaffenrath V: Cervicogenic headache: diagnostic criteria. Headache 1990, 30: 725–726.PubMedCrossRefGoogle Scholar
  84. 84.
    Dalessio JD: In Wolfs Headache and Other Head Pain, edn 3. Edited by Dalessio JD, Silberstein SD. New York: Oxford University Press; 1972: 71.Google Scholar
  85. 85.
    Tournier-Lasserve E, Joutel A, Melki J, et al.: Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19g12. Nat Genet 1993, 3:256–259.Google Scholar
  86. 86.
    Day JW, Raskin NH: Thunderclap headache: symptom of unruptured cerebral aneurysm. Lancet 1986, 2: 1247–1248.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Marc E. Lenaerts
  • James R. CouchJr.

There are no affiliations available

Personalised recommendations